Day 3, April 9

Vaccine Safety
09:00

Chair's opening remarks

Supply & Logistics
09:00

Chair’s opening remarks

Cancer & Immunotherapy
09:00

Chair's opening remarks

Respiratory
09:00

Chair’s opening remarks

Emerging and Infectious
09:00

Chair's opening remarks

Bioprocess & Manufacture
09:00

Chair's opening remarks

Partnerships
09:00

Chair's opening remarks

Vaccine safety in LMICs, outbreaks or emergencies

Outbreaks & Last mile delivery

Immune Profiling Technologies for Better Vaccine Design

Viral Associated Cancers

Respiratory Infections Strategy & Control

Vaccines for Enteric Diseases

Why the world needs HIV vaccines

Manufacturing 2.0

Tackling AMR

International Vaccination Funding Landscape

Vaccine Safety
09:10

The Safety Platform for Emergency Vaccines (SPEAC) Project

  • The Brighton Collaboration was created in 2000 with the goal of building trust in the safety of vaccines via rigorous science.
  • The Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration launched the Safety Platform for Emergency vACcines (SPEAC) Project on May 28, 2020.
  • SPEAC aims to support the emerging CEPI portfolio by creating practical solutions for harmonized safety assessment of CEPI vaccines by working:
    • To enhance vaccine safety assessment across CEPI development programs.
    • To harmonize vaccine safety monitoring during CEPI preclinical and clinical trials.
    • To provide a continuous improvement framework for the SPEAC program.
Cancer & Immunotherapy
09:10

The importance of therapeutic cancer vaccination for EBV-positive malignancies

  • EBV-positive cancers are richly infiltrated with diverse immune cells
  • Performing high dimensional phenotyping of EBV tumours
  • Exploring the antigen-specificity of infiltrating T-cells
  • How these results inform the development of therapeutic vaccine strategies
Respiratory
09:10

Regulatory guidance and pathway to developing next generation respiratory vaccines

Clinical Development
09:10

Why is an HIV vaccine needed?

  • Why is it taking so long to develop a vaccine
  • Update on current antiviral and bnAb pipeline
Dr Frank Tomaka, Senior Director, Clinical Lead HIV/STI Vaccines, Janssen Vaccines & Prevention B.V.
Partnerships
09:10

Funding health research and innovation – EU public private partnership

Bioprocess & Manufacture
09:25

Manufacturing technology showcase

Partnerships
09:40

How private investors and government donors work together to create a stronger impact on global health

Emerging and Infectious
09:55

Development of a synthetic Shigella conjugate vaccine until early clinical development

Vaccine Safety
10:10

Post-marketing safety considerations for a new vaccine developed exclusively for LMIC

  • How to address post-marketing considerations in a region with diverse pharmacovigilance capabilities.
  • The interaction of national stakeholder and manufacturers to overcome challenges to collect safety information in post-marketing?
Emerging and Infectious
10:10

ETEC vaccines for global health protection: Progress and trial updates

Bioprocess & Manufacture
10:25

Manufacturing technology showcase: Stockpiling heat stable oral vaccines to combat emerging disease

10:40

Networking Coffee Break

Vaccine Safety
11:30

The Ebola vaccine story; where are we now?

  • Wrapping up the DRC outbreak
  • The licensure process and unique pathway to regulatory approval
  • Policy & ethical considerations
  • Innovations, challenges and lessons learned throughout development
  • Implications for development of future emerging /re-emerging disease vaccines
Supply & Logistics
11:30

Panel: How can industry work with vaccine non-profits to improve last mile delivery?

  • What are the main challenges faced?
  • What should industry consider to better suit our needs?
    • Temperature stable vaccines, other considerations for products on the market
  • Case studies of what works / doesn’t work for current products
Bioprocess & Manufacture
11:30

Manufacturing and quality risk management during the vaccine development and manufacturing process

Vaccine Safety
12:00

How can mobile laboratories improve safety and evaluation of vaccines during outbreaks?

Respiratory
12:00

The interplay of virus, bacterial pathogens and exacerbation, an opportunity for vaccines?

Emerging and Infectious
12:00

Use of oral cholera vaccine as a key component to eliminate epidemic cholera as a public health threat

Bioprocess & Manufacture
12:00

Bridging the gap between Abs and vaccines: Successful application of monoclonal antibody (mAb) in infection field provides alternative strategy in prevention

12:30

Networking Lunch & Poster Session

13:29

DAY 3 AFTERNOON PLENARY OF CONGRESS: RENAISSANCE BALLROOM

An Vermeersch
13:40

How can we keep vaccines development and delivery sustainable for global health and prioritize equity?

  • Sustainable models for vaccine development for LMICs
  • How to approach infectious diseases, outbreaks and AMR pathogens that require considerable investment
  • Are close collaborations between public and private sectors the answer?
Kate O'Brien
14:00

How to achieve elimination of cervical cancer through HPV vaccines by 2030

15:40

Chair Closing Remarks and End of Congress

last published: 05/Mar/20 10:35 GMT